Dr. Aleksandra Walczak joined Ardigen’s Scientific Board to support the development of AI platforms for the discovery of cell therapies.

Topic:

September 7, 2021 – Ardigen, one of the world-leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, is proud to announce that Dr. Aleksandra Walczak joined the company’s Scientific Council. With a PhD in physical sciences and her knowledge and experience, she will support Ardigen’s work on platforms that use artificial intelligence to accelerate and optimize the discovery of modern cell therapies.

Dr. Aleksandra Walczak is an internationally recognized specialist in the field of computational biology and immunology. She has co-authored over 100 scientific publications, and one of her main research topics is the analysis of the diversity and complexity of receptors on the surface of B and T cells, which are involved in triggering an immune response.

Dr. Walczak is currently a research director at the National Center for Scientific Research (Center National de la Recherche Scientifique, CNRS) in France.

“Dr. Aleksandra Walczak has a long track record of advancing the science at the intersection of advanced statistical modeling with molecular biology of T-cell receptor repertoire. We are happy to receive her advice on the matters at the very core of our technology platforms” – said Agnieszka Blum, General Director of Immunology at Ardigen.

You might be also interested in:

Where AI Meets Wet-Lab: A Smarter Path to Biologics Discovery Success
Real-time analytics for Clinical Trials
Data Lakehouses: A Strategic Imperative for the Future of Clinical Studies?
Latest progress and tools for de novo generation of peptides

Contact

Ready to transform drug discovery?

Discover how one of the top AI CROs in the world, can be your trusted partner in revolutionizing drug discovery through AI.

Contact us today to learn more about our tailored solutions for empowering your drug development journey.

Send us a message and we will contact you back within 48 hours.

Newsletter

Become an insider

Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!